Health Canada today released the January 2014 issue of the Canadian Adverse Reaction Newsletter (CARN).
This issue includes an article on a class of cancer drugs known as VEGF receptor inhibitors, which are used to inhibit tumour cell growth, and the risk of a serious blood clotting disorder known as thrombotic microangiopathy (TMA).
It also includes an article on a potential increased risk of complications when Durepair Dura Regeneration Matrix, a collagen graft used for membrane repair in neurosurgery, is used with other products used to close or seal wounds.
The edition also contains a quarterly summary of health professional and consumer advisories.
The January 2014 edition of CARN is available on Health Canada's website at:www.healthcanada.gc.ca/carn